Eight-Membered-Ring Lactone Preparation
J. Am. Chem. Soc., Vol. 120, No. 30, 1998 7477
General Procedure for Radical Cyclizations. To a stirred
solution of a bromoacetate in benzene (0.015 M) under reflux
was added a mixture of tributylstannane (1.4 equiv) and AIBN
(0.1 equiv) in benzene via a syringe pump for 5 h (typical
scale: 1.0 mmol of bromoacetate in 67 mL of benzene). The
reaction mixture was further heated under reflux for 1 h and
concentrated under reduced pressure. The products were
separated by flash chromatography.
Oxocan-2-one (3c). From 207 mg of 3a, 48 mg (38%) of
3c was obtained after chromatographic separation (10:1-3:1
hexane/ether): 1H NMR (80 MHz, CDCl3) δ 1.56-2.05 (m, 8
H), 2.52 (t, 2 H, J ) 5.6 Hz), 4.32 (t, 2 H, J ) 5.6 Hz); 13C
NMR (50.3 MHz, CDCl3) δ 176.7, 67.83, 31.24, 30.90, 28.31,
25.79, 23.91; IR (neat, cm-1) 2920, 2860, 1725, 1450, 1232,
1130, 1097; MS (EI) m/z (relative intensity) 128 (M+, 0.1), 110
(6), 100 (19), 98 (16), 70 (27), 69 (48), 55 (100), 42 (70); HRMS
m/z calcd for C7H12O2 128.0837, found 128.0844.
5-Methyloxocan-2-one (4c). From 221 mg of 4a, 54 mg
(38%) of 4c was obtained after chromatographic separation (4:1
hexane/ethyl acetate): 1H NMR (80 MHz, CDCl3) δ 0.98 (d, 3
H, J ) 5.8 Hz), 1.25-2.00 (m, 7 H), 2.48-2.79 (m, 2 H), 4.32
(t, 2 H, J ) 5.6 Hz); 13C NMR (50.3 MHz, CDCl3) δ 176.4,
68.19, 36.12, 32.34, 32.29, 30.36, 30.09, 24.68; MS (EI) m/z
(relative intensity) 142 (M+, 0.2), 124 (4), 113 (19), 112 (11),
101 (10), 94 (21), 83 (39), 70 (38), 69 (51), 55 (100); HRMS
m/z calcd for C8H14O2 142.0995, found 142.0988.
5-Trimethylsilyloxocan-2-one (5c). From 150 mg of 5a,
54 mg (54%) of 5c was obtained after chromatographic
separation (5:1 hexane/ethyl acetate): 1H NMR (300 MHz,
CDCl3) δ -0.04 (s, 9 H), 0.45-0.55 (m, 1 H), 1.06-1.20 (m,
1 H), 1.46-1.61 (m, 2 H), 1.77-1.85 (m, 1 H), 1.96-2.09 (m,
2 H), 2.49 (ddd, 1 H, J ) 4.3, 9.0, 12.3 Hz), 2.70 (ddd, 1 H, J
) 4.1, 8.0, 12.3 Hz), 4.29-4.46 (m, 2 H); 13C NMR (50.3 MHz,
CDCl3) δ 176.6, 67.73, 32.58, 31.79, 29.08, 25.15, 24.41,
-3.777; IR (neat, cm-1) 2955, 2858, 2254, 1722, 1448, 1249,
1124, 837; MS (CI) m/z (relative intensity) 241 (M + 41, 1),
201 (M + 1, 40), 185 (38), 172 (7), 157 (3), 143 (10), 129 (3),
111 (53), 103 (3), 83 (100), 73 (55), 69 (21); HRMS m/z calcd
for C10H20O2Si 200.1233, found 200.1206.
2960, 2925, 1725, 1455, 1375, 1340, 1165, 1120, 1075; MS
(EI) m/z (relative intensity) 170 (M+, 1), 155 (1), 96 (100), 83
(45), 69 (28), 55 (45); HRMS m/z calcd for C10H18O2 170.1307,
found 170.1313.
8-Ethenyloxocan-2-one (14b). From 233 mg of 14a, 48 mg
(31%) of 14b and 82 mg (53%) of 14c were obtained after
chromatographic separation (8:1 hexane/ether): 1H NMR (80
MHz, CDCl3) δ 1.36-2.03 (m, 8 H), 2.43-2.59 (m, 2 H), 5.08-
5.43 (m, 3 H), 5.93 (ddd, 1 H, J ) 5.5, 10.0, 17.0 Hz); 13C
NMR (125.7 MHz, CDCl3) δ 176.4, 136.7, 115.8, 78.55, 37.33,
32.99, 29.14, 26.59, 24.02; IR (neat, cm-1) 2920, 2850, 1725,
1445, 1360, 1240; MS (EI) m/z (relative intensity) 154 (M+,
0.2), 126 (3), 111 (8), 98 (52), 80 (14), 69 (32), 55 (100); HRMS
m/z calcd for C9H14O2 154.0995, found 154.0975.
9-Methyl-2-oxabicyclo[4.2.1]nonan-3-one (14c). 1H NMR
(200 MHz, CDCl3) δ 1.06 (d, 3 H, J ) 7.1 Hz), 1.20-2.75 (m,
10 H), 4.61 (dd, 1 H, J ) 5.4, 7.7 Hz); 13C NMR (50.3 MHz,
CDCl3) δ 175.3, 83.55, 42.77, 40.20, 33.45, 32.25, 28.97, 22.36,
10.21; IR (neat, cm-1) 2940, 2860, 1730, 1720, 1430, 1350,
1250, 1190, 1170, 1105, 1040; MS (EI) m/z (relative intensity)
154 (M+, 3), 125 (2), 110 (89), 97 (72), 82 (27), 67 (64), 55
(100); HRMS m/z calcd for C9H14O2 154.0995, found 154.0999.
7,7-Dimethyl-8-ethenyloxocan-2-one (15c). From 340 mg
of 15a, 60 mg (25%) of 15c, 59 mg (25%) of 15e, and 55 mg
(23%) of 15d were obtained after chromatographic separation
(30:1-5:1 hexane/ether): 1H NMR (80 MHz, CDCl3) δ 0.89
(s, 3 H), 0.93 (s, 3 H), 1.10-2.00 (m, 6 H), 2.35-2.59 (m, 2
H), 4.76 (d, 1 H, J ) 6.0 Hz), 5.16-5.43 (m, 2 H), 5.89 (ddd,
1 H, J ) 5.9, 9.7, 17.3 Hz); 13C NMR (50.3 MHz, CDCl3) δ
175.4, 133.0, 117.8, 84.18, 39.56, 32.93, 29.12, 24.75, 21.97,
21.63; IR (neat, cm-1) 2960, 2920, 2855, 2830, 1720, 1460,
1350, 1325, 1270, 1205, 1140, 1105; MS (EI) m/z (relative
intensity) 182 (M+, 0.1), 126 (24), 111 (4), 82 (100), 69 (22),
55 (44); HRMS m/z calcd for C11H18O2 182.1307, found
182.1279.
8,8,9-Trimethyl-2-oxabicyclo[4.2.1]nonan-3-one (15d). 1H
NMR (300 MHz, CDCl3) δ 1.025 (d, 3 H, J ) 7.1 Hz), 1.138
(s, 3 H), 1.178 (s, 3 H), 1.29-1.39 (m, 1 H), 1.49 (d, 1 H, J )
14.3 Hz), 1.75-1.85 (m, 1 H), 1.89 (dd, 1 H, J ) 8.3, 14.3
Hz). 2.40-2.78 (m, 4 H), 3.97 (d, 1 H, J ) 4.7 Hz); 13C NMR
(125.7 MHz, CDCl3) δ 175.4, 93.18, 43.54, 42.13, 40.87, 40.33,
34.04, 33.70, 23.42, 22.29, 10.83; IR (neat, cm-1) 3010, 2920,
1705, 1460, 1215, 1160, 1140; MS (EI) m/z (relative intensity)
182 (M+, 1), 167 (1), 154 (3), 138 (19), 125 (42), 110 (16), 97
(32), 83 (16), 81 (37), 69 (40), 55 (100); HRMS m/z calcd for
C11H18O2 182.1307, found 182.1316.
8-Phenyloxocan-2-one (6c). From 283 mg of 6a, 107 mg
(52%) of 6c was obtained after chromatographic separation (8:
1
1-4:1 hexane/ether): H NMR (80 MHz, CDCl3) δ 1.60-2.20
(m, 8 H), 2.58 (t, 2 H), 5.69 (t, 1 H, J ) 6.9 Hz), 7.29-7.44
(m, 5 H); 13C NMR (50.3 MHz, CDCl3) δ 176.2, 140.2, 128.3,
127.7, 125.8, 79.63, 39.71, 32.93, 29.27, 26.53, 24.31; MS (EI)
m/z (relative intensity) 204 (M+, 0.5), 144 (17), 117 (25), 105
(26), 99 (59), 77 (36), 69 (36), 55 (100); HRMS m/z calcd for
C13H16O2 204.1150, found 204.1180.
6-Ethyl-8,8-dimethyl-2-oxabicyclo[3.3.0]octan-3-one
(15e). 1H NMR (300 MHz, CDCl3) δ 0.902 (t, 3 H, J ) 7.3
Hz), 0.985 (s, 3 H), 1.106 (s, 3 H), 1.21 (t, 1 H, J ) 12.7 Hz),
1.27-1.41 (m, 2 H), 1.58 (dd, 1 H, J ) 5.3, 12.7 Hz), 2.05-
2.20 (m, 1 H), 2.50 (d, 1 H, J ) 1.6 Hz), 2.52 (d, 1 H, J ) 5.0
Hz), 2.98-3.07 (m, 1 H), 4.39 (d, 1 H, J ) 6.3 Hz); 13C NMR
(50.3 MHz, CDCl3) δ 177.7, 93.20, 43.49, 41.79, 40.49, 39.98,
29.36, 25.61, 24.25, 23.39, 12.92; MS (EI) m/z (relative
intensity) 182 (M+, 2), 153 (12), 140 (2), 125 (17), 111 (7), 97
(100), 85 (13), 69 (45), 55 (59); HRMS m/z calcd for C11H18O2
182.1307, found 182.1271.
7,7-Dimethyloxocan-2-one (7c). From 235 mg of 7a, 83
mg (53%) of 7c was obtained after chromatographic separation
(7:1 hexane/ethyl acetate): 1H NMR (80 MHz, CDCl3) δ 0.96
(s, 6 H), 1.20-2.00 (m, 6 H), 2.45-2.62 (m, 2 H), 3.94 (s, 2
H); 13C NMR (50.3 MHz, CDCl3) δ 176.1, 75.36, 37.27, 36.51,
31.32, 28.74, 25.12, 22.01; MS (EI) m/z (relative intensity) 156
(M+, 0.5), 126 (5), 124 (11), 111 (3), 95 (3), 83 (15), 82 (100),
69 (19), 55 (37); HRMS m/z calcd for C9H16O2 156.1150, found
156.1178.
5,7,7-Trimethyloxocan-2-one (8c). From 210 mg of 8a, 35
mg (25%) of 8c was obtained after chromatographic separation
(8:1-4:1 hexane/ether): 1H NMR (300 MHz, CDCl3) δ 0.927
(s, 3 H), 0.969 (d, 3 H, J ) 6.8 Hz), 0.994 (s, 3 H), 1.14-1.95
(m, 5 H), 2.55-2.60 (m, 2 H), 3.80 and 4.08 (ABq, 2 H, J )
12.1 Hz); 13C NMR (50.3 MHz, CDCl3) δ 175.9, 75.53, 46.02,
6,8,8,9-Tetramethyl-2-oxabicyclo[4.2.1]nonan-3-one (16c).
From 275 mg of 16a, 54 mg (28%) of 16d and 30 mg (14%) of
16c were obtained after chromatographic separation (10:1-4:1
hexane/ether): 1H NMR (300 MHz, CDCl3) δ 0.935 (d, 3 H, J
) 7.2 Hz), 1.081 (s, 3 H), 1.09-1.18 (m, 1H), 1.146 (s, 3 H),
1.160 (s, 3 H), 1.568 and 1.692 (ABq, 2 H, J ) 14.4 Hz), 1.671
(dd, 1 H, J ) 4.5, 13.5 Hz), 2.18-2.24 (m, 1 H), 2.63 (ddd, 1
36.79, 36.18, 30.86, 28.68, 27.36, 25.59, 22.70; IR (neat, cm-1
)